explore -WSS

explore

author：fashion 2025-10-02 01:08:36 - browse：93835

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Wegovy, Zepbound and weight loss drugs that preserve muscle

WSS

CRISPR pioneers react to Casgevy, first gene

FDA's Woodcock to retire early next year

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Gain of function research would be limited under House proposal

How the political right came to back psychedelics to treat trauma

Congress must reauthorize a committee to support older Americans

knowledge

explore

knowledge

In Memoriam: Notable people who died in 2023

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Duchenne breakthrough therapy leaves behind pioneering families

Does good food count as health care? Study aims to find out

Trump demands the U.S. pay no more for drugs than other countries … again

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Malaria cases in Florida and Texas: Here’s what you need to know

Surge of respiratory disease in China has likely explanation

Psychedelics group wrestles with new pharma identity

FDA's Woodcock to retire early next year

knowledge

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Living with Fabry disease, a condition that causes chronic pain

N.Y. state detects polio case, first in the U.S. since 2013

Retired US general questions alleged Putin, Prigozhin meeting

N.Y. state detects polio case, first in the U.S. since 2013

Iowa House, Senate pass 6

hotspot

entertainment

leisure time

explore